ENTYVIO
Biological
Takeda Pharmaceuticals U.S.A., Inc.
Total Payments
$132.3M
Transactions
182,331
Doctors
22,505
Companies
4
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $30.8M | 59,355 | 14,106 |
| 2023 | $30.2M | 47,068 | 12,554 |
| 2022 | $28.2M | 40,177 | 10,472 |
| 2021 | $38.6M | 25,993 | 7,617 |
| 2020 | $2.7M | 8,975 | 4,054 |
| 2019 | $579,088 | 627 | 369 |
| 2017 | $1.1M | 136 | 18 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Royalty or License | $118.0M | 9 | 89.2% |
| Unspecified | $5.5M | 564 | 4.2% |
| Food and Beverage | $3.6M | 178,431 | 2.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3.2M | 895 | 2.4% |
| Consulting Fee | $1.2M | 406 | 0.9% |
| Travel and Lodging | $380,827 | 1,128 | 0.3% |
| Education | $211,446 | 885 | 0.2% |
| Grant | $130,000 | 3 | 0.1% |
| Space rental or facility fees (teaching hospital only) | $27,500 | 10 | 0.0% |
Payments by Type
General
$126.8M
181,767 transactions
Research
$5.5M
564 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| INFLAMMATORY BOWEL DISEASE RESEARCH COLLABORATION (IBDRC) STUDY AT U PENN | Takeda Pharmaceuticals U.S.A., Inc. | $1.3M | 0 |
| A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) | Takeda Pharmaceuticals U.S.A., Inc. | $803,991 | 1 |
| RECAP: Re-define the IBD disease burden status | Takeda Pharmaceuticals U.S.A., Inc. | $592,587 | 0 |
| Immune effects of vedolizumab with or without anti-TNF pre-treatment in T1D | Takeda Pharmaceuticals U.S.A., Inc. | $523,265 | 0 |
| Dose Finding Study of Vedolizumab for Graft-Versus-Host Disease (GvHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) | Millennium Pharmaceuticals, Inc. | $474,394 | 0 |
| An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease | Millennium Pharmaceuticals, Inc. | $246,682 | 0 |
| ASSESSING REAL-LIFE EXPERIENCE WITH VEDOLIZUMAB IN CROHN?S DISEASE AND ULCERATIVE COLITIS | Takeda Pharmaceuticals U.S.A., Inc. | $183,791 | 0 |
| Center of Excellence for PRecisiOn Medicine in IBD | Takeda Pharmaceuticals U.S.A., Inc. | $162,000 | 0 |
| ENTYVIO (VEDOLIZUMAB) LONG-TERM SAFETY STUDY: AN INTERNATIONAL OBSERVATIONAL PROSPECTIVE COHORT STUDY COMPARING VEDOLIZUMAB TO OTHER BIOLOGIC AGENTS IN PATIENTS WITH ULCERATIVE COLITIS OR CROHN'S DISEASE | Takeda Pharmaceuticals U.S.A., Inc. | $141,481 | 1 |
| A Dose-Finding Study of Vedolizumab for Treatment of Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease (GvHD) in Participants Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) | Millennium Pharmaceuticals, Inc. | $140,487 | 5 |
| INTERROGATING MECHANISMS OF ACTION UNDERLYING CLINICAL EFFICACY OF VEDOLIZUMAB FOR INFLAMMATORY BOWEL DISEASES | Takeda Pharmaceuticals U.S.A., Inc. | $129,365 | 0 |
| OPTIMIZING THERAPEUTIC RESPONSE TO VEDOLIZUMAB IN CROHN'S DISEASE PATIENTS WITH ASSESSMENT OF INTESTINAL BARRIER FUNCTION | Takeda Pharmaceuticals U.S.A., Inc. | $103,985 | 0 |
| IBD PATIENTS? PREFERENCES FOR SUBCUTANEOUS OR INTRAVENOUS ADMINISTRATION OF BIOLOGICS ? A MIXED METHODS STUDY | Takeda Pharmaceuticals U.S.A., Inc. | $103,652 | 0 |
| Entyvio-Vedolizumab- Long Term Study | Takeda Pharmaceuticals U.S.A., Inc. | $101,927 | 0 |
| DEFINING PREDICTORS OF RADIOLOGICAL TRANSMURAL RESPONSE TO VEDOLIZUMAB IN SMALL BOWEL CROHN?S DISEASE THROUGH SERUM PROTEOMIC BIOMARKERS | Takeda Pharmaceuticals U.S.A., Inc. | $61,075 | 0 |
| Defining Predictors of Radiological Transmural Response to Vedolizumab in Small Bowel Crohn's disease through Serum Proteomic Biomarkers | Takeda Pharmaceuticals U.S.A., Inc. | $61,075 | 0 |
| MLN0002-1015(PH Phase 1b) | Millennium Pharmaceuticals, Inc. | $53,182 | 0 |
| Immunogenicity of the Herpes Zoster Subunit Vaccine | Takeda Pharmaceuticals U.S.A., Inc. | $52,703 | 0 |
| LEVERAGING SOCIAL MEDIA FOR EDUCATING PATIENTS WITH INFLAMMATORY BOWEL DISEASE | Takeda Pharmaceuticals U.S.A., Inc. | $46,810 | 0 |
| IMMUNOINFLAMMATORY EFFECT OF PRIOR EXPOSURE TO ANTI-TNF THERAPY | Takeda Pharmaceuticals U.S.A., Inc. | $44,986 | 0 |
Top Doctors Receiving Payments for ENTYVIO
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | New York, NY | $124.1M | 644 |
| , MD | Gastroenterology | Louisville, KY | $352,419 | 163 |
| , D.O | Gastroenterology | Fort Hood, TX | $237,900 | 238 |
| , M.D | Gastroenterology | Maywood, IL | $230,378 | 138 |
| , DO | Gastroenterology | Ft Carson, CO | $199,673 | 83 |
| , MS MD PHD | Allergy & Immunology | Williamsville, NY | $182,302 | 131 |
| , M.D | Gastroenterology | New York, NY | $130,337 | 19 |
| , M.D | Internal Medicine | Chicago, IL | $125,926 | 80 |
| , MD | Gastroenterology | Houston, TX | $120,709 | 125 |
| , MD | Internal Medicine | Miami, FL | $119,705 | 94 |
| , MD | Internal Medicine | Orlando, FL | $98,259 | 52 |
| , M.B.B.S | Gastroenterology | La Jolla, CA | $87,867 | 55 |
| , MD | Gastroenterology | New York, NY | $78,112 | 102 |
| , MD | Gastroenterology | Chicago, IL | $76,698 | 41 |
| , MD | Gastroenterology | New York, NY | $76,677 | 32 |
| , M.D | Gastroenterology | Coral Springs, FL | $72,931 | 103 |
| , MD | Gastroenterology | Pittsburgh, PA | $68,434 | 43 |
| Russell Cohen | Gastroenterology | Burr Ridge, IL | $63,740 | 47 |
| , MD | Specialist | Pittsburgh, PA | $61,414 | 20 |
| , MD | Gastroenterology | Oklahoma City, OK | $61,217 | 37 |
| , M.D | Gastroenterology | Nashville, TN | $58,941 | 61 |
| , M.D | Gastroenterology | West Hills, CA | $58,473 | 58 |
| , MD | Gastroenterology | Seattle, WA | $56,342 | 74 |
| David Rubin | Gastroenterology | Burr Ridge, IL | $54,133 | 19 |
| , MD | Gastroenterology | Nashville, TN | $53,251 | 42 |
Ad
Manufacturing Companies
Product Information
- Type Biological
- Total Payments $132.3M
- Total Doctors 22,505
- Transactions 182,331
About ENTYVIO
ENTYVIO is a biological associated with $132.3M in payments to 22,505 healthcare providers, recorded across 182,331 transactions in the CMS Open Payments database. The primary manufacturer is Takeda Pharmaceuticals U.S.A., Inc..
Payment data is available from 2017 to 2024. In 2024, $30.8M was paid across 59,355 transactions to 14,106 doctors.
The most common payment nature for ENTYVIO is "Royalty or License" ($118.0M, 89.2% of total).
ENTYVIO is associated with 20 research studies, including "INFLAMMATORY BOWEL DISEASE RESEARCH COLLABORATION (IBDRC) STUDY AT U PENN" ($1.3M).